

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

CHANGE OF COMPANY SECRETARY, CHIEF FINANCIAL OFFICER AND AUTHORIZED REPRESENTATIVE

The Board announces that Ms. Yip Pui Ling, Rebecca resigned as acting Company Secretary and Chief Financial Officer, and Ms. Poon Lei Yung resigned as acting Authorized Representative of the Company, both with effect from 18 February 2011.

Mr. Mui Chi Hung has been appointed as Company Secretary, Chief Financial Officer and Authorized Representative of the Company with effect from 18 February 2011.

The board of directors (the “**Board**”) of Lansens Pharmaceutical Holdings Limited (the “**Company**”) announces that Ms. Yip Pui Ling, Rebecca (“**Ms. Yip**”) resigned as acting Company Secretary and Chief Financial Officer of the Company, and Ms. Poon Lei Yung (“**Ms. Poon**”) resigned as acting Authorized Representative of the Company, for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XI of the Hong Kong Companies Ordinance with effect from 18 February 2011. Ms. Yip will continue to be the non-executive Director of the Company. Ms. Yip and Ms. Poon confirmed that they have no disagreement with the Board and there is no other matter in relation to their resignations that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that Mr. Mui Chi Hung (“**Mr. Mui**”) has been appointed as Company Secretary, Chief Financial Officer and Authorized Representative of the Company with effect from 18 February 2011. Mr. Mui, age 44, has over 19 years of experience in financing, auditing and accounting. Prior to joining the Company, Mr. Mui held various senior positions in different listed groups and international accounting firms, including PricewaterhouseCoopers, Far East Consortium Group and Rising Development Group, where he spent 7 years serving as a Financial Controller, Company Secretary and Executive Director. Mr.

Mui obtained his master's degree in Professional Accounting from the Hong Kong Polytechnic University in 2002 and his bachelor's degree in Management majoring in Accounting from the University of Lethbridge in Canada in 1992. Mr. Mui is currently a member of AICPA and HKICPA.

The Board takes this opportunity to warmly welcome Mr. Mui on taking up the new positions.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Stephen Burnau Hunt
Chairman

Hong Kong, 18 February 2011

As at the date of this announcement, the executive Directors are Mr. Xu Jun, Mr. Liu Xiao Dong; the non-executive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Mr. Tang Jun, Ms. Tao Fang Fang, Ms. Yip Pui Ling, Rebecca; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.